Neuralink.
Jun 2025
Four countries
In existence
Don't take our word for it — read the reporting.
Tap any outlet to open the original article. Figures reflect publicly reported information.
Functional use in 26 implanted participants.
One implant. Three senses.
Telepathy
Control a computer by thinking — cursor, keyboard, robotic arm.
Voice
Speech decoded from thought, for people who have lost the ability to speak.
Blindsight
Sight written directly into the visual cortex, bypassing the eye.
Bandwidth is the moat.
Potential across serious neurological conditions.
The mark keeps stepping up.
The company, in six figures.
Who's already on the cap table.
Still private — no announced IPO.
Private-market access is available now.
No IPO has been announced. Eligible investors may gain exposure to Neuralink through a private investment vehicle before any potential public listing.
2026 is the scale year
High-volume production, automated surgery and the first Blindsight implant are all on this year's stated plan.
Milestones move the price
$3.5B → $9.65B → secondary marks several times higher. Company milestones may affect private-market valuations, although no increase in value or liquidity event is assured.
What every investor should weigh honestly.
Pre-revenue, pre-approval.Nothing is cleared for sale in the US. The trial record runs to 2031.
Real competition.Synchron, Precision and Paradromics are in humans — and China's first BCI is already cleared to sell.
Surgical and safety risk.Brain implants carry hard risks; the earliest device saw threads retract.
Illiquid and speculative.Private stock can't be freely sold. You may hold for years — or lose the entire investment.
Project
Ask Singular
A 24/7 AI. Ask anything about your investment, any hour.
Client Portal
One login. Your position, every document, every update.
operations@singularventure.com
+1 (973) 229-2497
The deal closes.Your concierge opens.
Invest in Neuralink through a Singular Venture SPV.
Eligible investors buy an interest in a Singular Venture SPV. The SPV purchases and holds the Neuralink shares. Three steps, start to finish.
New York